Ren Xiaodan, Shi Yu, Li Guizhong
The Second Affiliated Hospital of Army Medical University.
Beibei Traditional Chinese Medical Hospital, Chongqing, China.
Medicine (Baltimore). 2020 Nov 25;99(48):e23261. doi: 10.1097/MD.0000000000023261.
Assessing the effectiveness and safety of Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19 is the main purpose of this systematic review protocol.
The following electronic databases will be searched from their respective inception dates to October 1, 2020: PubMed, MEDLINE, the Cochrane Library, Embase, WorldSciNet, Ovid, the Allied and Complementary Medicine Database, the Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database (VIP), the Wanfang Database, and the China Biology Medicine Disc. All published randomized controlled trials in English or Chinese related to Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19 will be included. The primary outcome is the time and rate of appearance of coughing. The secondary outcomes are the length of hospital stay. Two reviewers will conduct the study selection, data extraction, and assessment independently. The assessment of risk of bias and data synthesis will be conducted with RevMan V.5.2.
The results will provide a high-quality synthesis of current evidence for researchers in this subject area.
The conclusion of our study will provide an evidence to judge whether traditional Chinese medicine formula Xiaoqinglong decoction is an effective intervention for patients with cough caused by COVID-19.
Formal ethical approval is not necessary as the data cannot be individualized. The results of this protocol will be disseminated in a peer-reviewed journal or presented at relevant conferences.
CRD42020202079.
评估中药方剂小青龙汤治疗新型冠状病毒肺炎所致咳嗽的有效性和安全性是本系统评价方案的主要目的。
将从各数据库建库之日起检索至2020年10月1日,检索以下电子数据库:PubMed、MEDLINE、Cochrane图书馆、Embase、WorldSciNet、Ovid、补充与替代医学数据库、科学引文索引、中国生物医学文献数据库、中国知网、维普中文科技期刊数据库、万方数据库和中国生物医学文献光盘数据库。纳入所有已发表的关于中药方剂小青龙汤治疗新型冠状病毒肺炎所致咳嗽的英文或中文随机对照试验。主要结局是咳嗽出现的时间和发生率。次要结局是住院时间。两名评价员将独立进行研究筛选、数据提取和评估。将使用RevMan V.5.2进行偏倚风险评估和数据合成。
结果将为本学科领域的研究人员提供高质量的当前证据综合。
我们研究的结论将为判断中药方剂小青龙汤是否是治疗新型冠状病毒肺炎所致咳嗽患者的有效干预措施提供证据。
由于数据无法个体化,无需正式伦理批准。本方案的结果将在同行评审期刊上发表或在相关会议上展示。
PROSPERO注册号:CRD42020202